ACRV: Acrivon Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 1 sales totaling $585 in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-05 | Miller Mary | Officer | $585 |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-13 | 13G amendment | Sands Capital Life Sciences Pulse Fund II, L.P. | 5.30% | SEC |
Institutional ownership (Q2 2026)
46 institutions reported holding $35.65M of Acrivon Therapeutics, Inc. on Form 13F (44 the quarter before). 6 opened a new position and 4 sold out. Shares held by institutions: +32%.
| Largest holders | Shares | Value |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12,229,396 | $21.77M |
| Sands Capital Alternatives, LLC | 2,289,271 | $4.07M |
| VANGUARD CAPITAL MANAGEMENT LLC | 952,008 | $1.69M |
| WELLINGTON MANAGEMENT GROUP LLP | 888,130 | $1.58M |
| RENAISSANCE TECHNOLOGIES LLC | 758,863 | $1.35M |
| TWO SIGMA INVESTMENTS, LP | 641,498 | $1.14M |
| MARSHALL WACE, LLP | 531,856 | $947K |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 378,900 | $674K |
| GEODE CAPITAL MANAGEMENT, LLC | 265,241 | $472K |
| BlackRock, Inc. | 239,112 | $426K |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.